SCHEMBL3920922

SCHEMBL3920922

O=C1C(Cc2ccccc2)NC2(CCN(S(=O)(=O)c3cc(Cl)sc3Cl)CC2)N1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CXCR3 P49682 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPK1 P28482 1/20 0.37
TRPV4 Q9HBA0 1/20 0.37
TSHR P16473 2/20 0.37
MAPT P10636 2/20 0.37
EPHX2 P34913 1/20 0.37
ACLY P53396 1/20 0.37
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
F10 P00742 1/20 0.36
USP2 O75604 1/20 0.35
CYP2D6 P10635 1/20 0.35
MMP2 P08253 2/20 0.35
MMP13 P45452 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CCR5 P51681 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3917724 0.84 CYP2D6 (0.51) SMN1; SMN2MAPK1TSHRGAAHTT
SCHEMBL3920599 0.82 PKM (0.42) PKMTDP1CXCR3SMN1; SMN2TSHR
SCHEMBL3919576 0.82 MMP2 (0.51) CXCR3SMN1; SMN2TSHRMAPTGAA
SCHEMBL3926286 0.81 ALDH1A1 (0.55) PKMLMNATDP1SMN1; SMN2MAPK1
SCHEMBL3915497 0.81 CYP2D6 (0.50) CXCR3SMN1; SMN2TSHRGAACYP2D6
SCHEMBL3917067 0.80 MEN1 (0.42) LMNACXCR3SMN1; SMN2TSHRMAPT
SCHEMBL3925408 0.80 SMN1; SMN2 (0.48) PKMLMNASMN1; SMN2TSHRMAPT
SCHEMBL3915453 0.79 HSD11B1 (0.48) LMNACXCR3SMN1; SMN2TSHRGAA
SCHEMBL3918144 0.77 MMP2 (0.53) SMN1; SMN2TSHRMAPTGAAHTT
SCHEMBL3915181 0.77 LMNA (0.55) PKMLMNASMN1; SMN2MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 PKM 1588/4885LMNA 1640/4885TDP1 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.